Arca
Skip to content
Tools
Tools

Hairy cell leukemia

Drug research and approvals for hairy cell leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 14 studies of hairy cell leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 14
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 14 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 2 12

Phase 1 or earlier 4

How its trials ended

105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 35 whose ending is known, 34% met their primary endpoint, 0% missed it and 66% stopped early.

  • Completed, result not reported3937%
  • Ongoing2928%
  • Met its primary endpoint1211%
  • Stopped: other or unclear1110%
  • Stopped: enrollment or feasibility77%
  • Stopped: sponsor or business decision33%
  • Stopped: funding22%
  • Status unknown22%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Jan 9, 2015A pivotal multicenter trial of moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaCAT-8015 (moxetumomab pasudotox)MedImmune LLCOngoing

FDA orphan designations

Approved first, then open designations, newest first
Feb 26, 1993Leustatin InjectionTreatment of hairy cell leukemia.R. W. Johnson Pharmaceutical Research InstituteApproved
Oct 11, 1991NipentSingle agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.SuperGen, Inc.Approved
May 16, 2008BlinatumomabTreatment for hairy cell leukemia.Amgen, Inc.Designated
Aug 10, 2004(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-rib…Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell…Mundipharma Research Ltd.Designated
May 3, 1990Granulocyte macrophage-colony stimulating factorTreatment of neutropenia due to hairy cell leukemia.Schering CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.